The MFDS has begun a preliminary review of the vaccine for COVID-19 in Moderna and Pfizer. The preliminary review is to review the submitted clinical data in advance and to quickly determine whether to grant permission when the company applies for an item permit by adding non-clinical and quality data in the future.

The divalent vaccine, which Moderna and Pfizer applied for a preliminary review, is a vaccine that expresses each antigen for the initial coronavirus (Wuhan) and the omicron mutation virus BA. It is a combo vaccine that combines two antigens in half, and the two companies began developing it early this year and announced major clinical results in June. The two vaccines were found to have pro